How to use the anti-HIV jab — and where to find it

South Africa has significantly advanced its HIV prevention strategy with the free rollout of long-acting injectable cabotegravir (CAB-LA), known as Apretude, at 360 government clinics across six provinces. This development, following regulatory approval by the South African Health Products Regulatory Authority (SAHPRA) in December 2022, marks a critical step in addressing the nation's high HIV burden. The legal framework underpinning this initiative is rooted in the constitutional right to access healthcare services (Section 27 of the Constitution), supported by the National Health Act 61 of 2003 and the Medicines and Related Substances Act 101 of 1965. While enhancing access, the rollout also necessitates careful consideration of patient rights, particularly informed consent, and equitable distribution, aligning with the country's National Strategic Plan on HIV, TB and STIs.

For legal professionals, this rollout raises a spectrum of considerations, from the regulatory pathways that facilitated its approval and distribution to the constitutional and statutory rights of patients accessing this innovative treatment. It underscores the intricate interplay between public health policy, pharmaceutical regulation, and fundamental human rights, particularly the right to access healthcare services. This article will delve into the legal and regulatory underpinnings of CAB-LA's availability in South Africa, examining the framework that supports its free provision and the implications for practitioners navigating this evolving public health terrain.

Further giving effect to these constitutional mandates is the National Health Act 61 of 2003, which provides a comprehensive framework for a structured and uniform national health system. The Act outlines the responsibilities of national, provincial, and local governments in providing health services and establishes the rights and duties of healthcare users. It mandates that primary healthcare services at clinics and community health centres are free for everyone, and specifically ensures free healthcare for pregnant or lactating women and children under six, regardless of their medical aid status. The Medicines and Related Substances Act 101 of 1965, on the other hand, governs the regulation, registration, manufacturing, and distribution of medicines, with the South African Health Products Regulatory Authority (SAHPRA) being the key body responsible for ensuring the safety, quality, and efficacy of health products. South Africa's commitment to addressing HIV is also articulated in its National Strategic Plans on HIV, TB and STIs, with the current 2023-2028 plan emphasizing innovative, people-centred interventions to enhance access to prevention and treatment services.

Furthermore, the equitable distribution of CAB-LA across provinces and clinics, as well as the training of healthcare professionals for its administration, are practical and legal considerations. The National Health Act envisages a unified health system, but disparities in resource allocation and service delivery persist. The success of this rollout will depend on overcoming these systemic challenges to ensure that the 'jab' reaches those who need it most, without discrimination, consistent with Section 9 of the Constitution which prohibits unfair discrimination, including on the basis of HIV status.

Looking ahead, practitioners should monitor the ongoing implementation of CAB-LA, particularly regarding its reach into underserved communities, the efficacy of informed consent protocols in practice, and any potential legal challenges related to access or adverse events. The success of this initiative will not only be measured by a reduction in new HIV infections but also by its adherence to the principles of human rights, equity, and patient autonomy that are foundational to South African law. This rollout serves as a powerful reminder of the legal profession's role in advocating for and safeguarding public health advancements within a rights-based framework.